Jonas Faartoft Jensen

Mr. Jonas Faartoft Jensen

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2025 in European Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
MJMaren Poulsgaard Jørgensen
Maren Poulsgaard Jørgensen
AØAndreas Kiesbye Øvlisen
Andreas Kiesbye Øvlisen
Jonas Faartoft JensenJonas Faartoft Jensen
Jonas Faartoft Jensen
TETarec Christoffer El-Galaly
Tarec Christoffer El-Galaly
MDMaiken Glud Dalager
Maiken Glud Dalager
MSMarianne Tang Severinsen
Marianne Tang Severinsen
Introduction: Mastocytosis is a group of rare heterogeneous diseases with a prevalence previously found to be 10–23 per 100,000 persons. More awareness and improvements in the diagnostic methods in later years have led to more patients being diagnosed. Here, we set out to present the prevalence and incidence rate of mastocytosis among the adult Danish population. By merging data from the Danish National Patient Register, the Danish Pathology Register and the Danish Cancer Register we included all adult patients (≥ 18 years) diagnosed with mastocytosis in Denmark prior to 2022. A cohort of 1,594 patients with mastocytosis was identified. The prevalence of mastocytosis was 27.43 per 100,000 persons (95% confidence interval [CI]: 25.95–28.96) as of January 1, 2022, and the 25-year average incidence rate between 1997 and 2021 was 1.21 per 100,000 persons (95%CI: 1.02–1.40) with an increasing incidence rate since 2002. We found a higher prevalence of mastocytosis among adults in the Danish population than previously reported, and an increasing incidence rate during the last 20 years. Increased awareness of the disease and better diagnostic methods most likely contributed to this.

21 July 2025 in British Journal of Haematology
Verified
Journal Article
Open access
RJRikke Hedegaard Jensen
Rikke Hedegaard Jensen
CTChristian Teglgaard
Christian Teglgaard
Jonas Faartoft JensenJonas Faartoft Jensen
Jonas Faartoft Jensen
JBJoachim Baech
Joachim Baech
CMClaus Werenberg Marcher
Claus Werenberg Marcher
MSMarianne Tang Severinsen
Marianne Tang Severinsen
Summary: Anthracycline‐containing chemotherapy is associated with cardiovascular diseases (CVDs). While knowledge regarding the extent of cardiotoxicity in adult patients with acute myeloid leukaemia (AML) is sparse, anthracyclines remain a key component in the treatment. To address this, 1379 adult AML patients treated with anthracycline‐containing chemotherapy between 2000 and 2020 were matched to 6895 comparators from the Danish background population and followed for a median of 11.8 and 12.8 years respectively. The risk of congestive heart failure (CHF) was higher in AML patients compared to the comparators throughout the entire follow‐up period with adjusted hazard ratios (HRs) ranging from 15.0 (95% CI: 7.02–32.1) after 3 months to 2.68 (95% CI: 1.67–4.30) after 15 years. The risk of non‐CHF CVD was initially higher in AML patients (adjusted HR: 9.16 [95% CI: 6.61–12.7] after 3 months) but converged to that of the comparators after approximately 10 years. Among AML patients, increasing age and male sex were identified as risk factors of CHF and non‐CHF CVD. In summary, AML patients treated with anthracycline‐containing chemotherapy had an elevated risk of CVD, particularly during the first years after treatment initiation. Increased focus on early detection and cardioprotective strategies may help mitigate the harmful effects of anthracyclines in the future.

7 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
EMEva Futtrup Maksten
Eva Futtrup Maksten
Jonas Faartoft JensenJonas Faartoft Jensen
Jonas Faartoft Jensen
GTGitte Thomsen
Gitte Thomsen
DZDitte Rechter Zenas
Ditte Rechter Zenas
MJMaren Poulsgaard Jørgensen
Maren Poulsgaard Jørgensen
MSMarianne Tang Severinsen
Marianne Tang Severinsen
Background/Objectives: Patients with chronic myeloid leukemia (CML) have a long life expectancy due to modern treatment. However, treatment may have adverse effects that hamper work ability. Methods: Patients aged 25–60 years diagnosed in 2002–2020 were included in this nationwide matched cohort study examining work ability from diagnosis (index date), including the need for permanent disability compensation (flexible job or disability pension). Each patient was matched 1:5 on sex, birth year, and level of comorbidity with citizens from the general Danish population without CML. The risks of requiring flexible job and disability pension were calculated by cause-specific hazard ratios (HRs) using Cox proportional hazards regression, and the Aalen–Johansen estimator was used to determine cumulative risks. Results: A total of 489 patients with CML and 2445 matched comparators were included. The median age was 46 years, and males comprised 59.5% of the cohort. Matched comparators were more likely to work at index date and 1, 3, 5, and 10 years after the index date (p < 0.001). The HRs of requiring both flexible job (HR 8.7 (95% confidence interval (CI): 6.1;12.2, p < 0.001)) and disability pension (HR 3.7 (95% CI: 2.8;4.9, p < 0.001)) were higher among patients diagnosed with CML compared to matched comparators. The cumulative risk of requiring flexible job and disability pension also increased in patients with CML compared to matched comparators (p < 0.001). Conclusions: Patients with CML have a reduced work ability compared to the general population. More research is needed to determine the cause of their loss of ability to work.

2 July 2025 in British Journal of Haematology
Verified
Journal Article
Open access
NNNanna N. Nielsen
Nanna N. Nielsen
Jonas Faartoft JensenJonas Faartoft Jensen
Jonas Faartoft Jensen
AØAndreas Øvlisen
Andreas Øvlisen
DZDitte R. Zenas
Ditte R. Zenas
CSClaudia Schöllkopf
Claudia Schöllkopf
MSMarianne Tang Severinsen
Marianne Tang Severinsen
Summary: Treatment‐related infertility is of great concern to younger long‐term survivors of acute leukaemia (AL). This study aimed to assess birth rates and cumulative incidences of first live birth, use of assisted reproduction technology (ART) and pregnancy outcomes in AL survivors compared to the Danish general population. Patients aged 18–45 years at AL diagnosis, alive and in remission 3 years after the date of diagnosis (index date), were included and matched 1:10 with leukaemia‐free comparators on sex, age and parenthood status. A total of 401 AL survivors (183 females; 218 males) and 4010 matched comparators were followed for a median of 9.9 years. The median age at index was 37 years in females and 36 years in males. AL survivors had lower birth rates (incidence rate ratio: 0.77, 95% confidence interval: 0.61–0.99), lower 10‐year cumulative incidences (females: 20.1% vs. 27.8%; males: 22.3% vs. 29.9%), a higher use of ART (females: 25.5% vs. 14.1%; males: 55.9% vs. 12.2%), but no higher degree of adverse pregnancy outcomes. This underscores the importance of informing patients of fertility‐preservation options as well as of the risk of treatment‐related infertility.

2 June 2025 in eJHaem
Verified
Journal Article
Open access
SBSimone Juline Brommann
Simone Juline Brommann
LPLinea Pilgaard
Linea Pilgaard
Jonas Faartoft JensenJonas Faartoft Jensen
Jonas Faartoft Jensen
AOAnne Estrup Olesen
Anne Estrup Olesen
DKDaniel Tuyet Kristensen
Daniel Tuyet Kristensen
MSMarianne Tang Severinsen
Marianne Tang Severinsen
Background: The hypomethylating agent azacitidine (AZA) is the most widely used first‐line treatment for patients with higher‐risk myelodysplastic syndromes (MDS) due to its survival benefits. Effective management of higher‐risk MDS requires addressing not only clinical outcomes but also the burden of healthcare resource utilisation (hospitalisations and transfusions), which remains poorly characterised.Methods: We conducted a retrospective, population‐based study of patients diagnosed with higher‐risk MDS treated with AZA between 2010 and 2022. We collected clinical data, including transfusions and hospitalisations, by detailed review of medical records from the initiation of AZA and up to 12 cycles.Results: In total, 103 patients were included, and 94% required supportive care during treatment. Healthcare resource utilisation peaked during the first four cycles. Hospitalisation was necessary for 75% of the patients, and 28% were hospitalised ≥ 3 times. Red blood cell (RBC) transfusions were required for 78% of the patients in the first cycle, and 30% achieved RBC transfusion independence.Conclusion: This study highlights the substantial healthcare resource utilisation for patients with higher‐risk MDS receiving AZA, which emphasises the importance of considering these factors in treatment planning.Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

28 December 2024 in eJHaem
Verified
Journal Article
Open access
LPLaura Schou Pedersen
Laura Schou Pedersen
NKNadja Nørholm Klausen
Nadja Nørholm Klausen
Jonas Faartoft JensenJonas Faartoft Jensen
Jonas Faartoft Jensen
EBEmilis Danielsen Bacevičius
Emilis Danielsen Bacevičius
PBPeter Brown
Peter Brown
LJLasse Hjort Jakobsen
Lasse Hjort Jakobsen
Background: There is limited knowledge of the long‐term effects on the immune system after treatment for diffuse large B‐cell lymphoma (DLBCL).Methods: This study included DLBCL patients from the Danish Lymphoma Registry who obtained complete remission (CR) after (R)‐CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)‐like immunochemotherapy. Each R+ CHOP‐like treated patient was matched to five comparators from the Danish background population and furthermore compared to R− CHOP‐like treated patients. Incidence rate ratios (IRRs) and risk differences (RDs) were calculated for a wide range of infections, autoimmune conditions, and immune deficiencies (AC‐IDs) combined and by subtypes.Results: R+ CHOP‐like treated patients had a higher risk of infections overall (IRR 1.5, 95% confidence interval [CI] 1.4–1.7: 10‐year RD 5.0%, 95% CI 2.2%–7.8%) and for a majority of the subtypes than matched comparators. Likewise, they had a higher risk of AC‐IDs overall (IRR 1.4, 95% CI 1.1–1.7; RD 0.8%, 95% CI 0.7%–2.2%) than matched comparators, however only of clinical relevance for three subtypes; autoimmune diseases of the endocrine system, sarcoidosis and immune deficiencies. The addition of rituximab to CHOP‐like therapy did not alter the incidence rates (IR) of infections overall (IRR 1.1, 95% CI 0.9–1.3) or AC‐IDs overall (IRR 0.8, 95% CI 0.5–1.3) compared to CHOP‐like therapy alone, although the IR for respiratory infections was significantly elevated (IRR 1.5, 95% CI 1.1–2.1). However, an increased use of IVIG treatment was observed among R+ CHOP survivors.Conclusion: R‐CHOP‐like treated patients face an increased risk of infections and AC‐IDs overall compared with the background population. The risk of infections and AC‐IDs did not change overall after the addition of rituximab to CHOP, however, an increased risk of respiratory infections is notable. These findings could highlight the need for expanded vigilance and prophylaxis strategies.